PD Dr. Hans Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) (2020) Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, et al. Conference contribution LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, et al. Conference contribution IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL (2020) Rossmanith T, Koehm M, Kiltz U, Rech J, Burmester GR, Kellner H, Bulczak-Schadendorf A, et al. Conference contribution STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY (2020) Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, et al. Conference contribution FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT (2020) Bayat S, Simon D, Pecherstorfer C, Ellmann H, Figueiredo C, Englbrecht M, Hueber A, et al. Conference contribution TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS (2020) Raimondo MG, Rauber S, Luber M, Rigau AR, Weber S, Anchang CG, Agarwal R, et al. Conference contribution Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis (2020) Friedberger A, Figueiredo C, Grimm A, Oliveira I, Bäuerle T, Rech J, Kleyer A, et al. Journal article Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study (2020) McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, et al. Journal article A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations (2020) Sokolova MV, Simon D, Nas K, Zaiss M, Luo Y, Zhao Y, Rech J, Schett G Journal article Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study (2020) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article